Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This non-interventional study will meta-analyze overall survival outcomes among the participants with metastatic colorectal cancer (mCRC) with available V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) status, who received firstline treatment with bevacizumab containing treatment regimen in routine clinical practice. The study leveraging secondary data from existing cohorts in the United Stats of America (USA), Germany, Australia, and Denmark.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| mCRC Participants | Data of mCRC participants who received first-line treatment with bevacizumab-containing regimen or with chemotherapy alone and had KRAS-mutant status and mCRC participants who received first-line treatment with bevacizumab-containing regimen or an anti-epidermal growth factor receptor (EGFR)-containing regimen and had KRAS wild type status, will be collected retrospectively. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Anti-EGFR-Containing Regimen | Drug | Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Overall Survival (OS) in Participants With mCRC and a Documented KRAS Mutation who Received Bevacizumab-Containing Treatment or Chemotherapy Alone in Routine Clinical Practice | start of first-line therapy to death from any cause, or to last date known that participant is alive (retrospective data collection over approximately 9 years) |
| Measure | Description | Time Frame |
|---|---|---|
| OS in Participants With mCRC and a Documented KRAS Wild Type Status who Received Bevacizumab-Containing Treatment or Anti-EGFR Treatment in Routine Clinical Practice | start of first-line therapy to death from any cause, or to last date known that participant is alive (retrospective data collection over approximately 9 years) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
N/A
Not provided
Not provided
Not provided
Participants with mCRC and known KRAS status who received bevacizumab as first-line treatment.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Germany: PEI Clinical Trials | Hoffmann-La Roche | Study Director |
Not provided
Not provided
Not provided
Not provided
Not provided
| Bevacizumab-containing regimen | Drug | Study protocol does not specify any particular bevacizumab containing regimen. The data will be collected retrospectively. |
|
|
| Chemotherapy | Drug | Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively. |
|
| ID | Term |
|---|---|
| D015179 | Colorectal Neoplasms |
| ID | Term |
|---|---|
| D007414 | Intestinal Neoplasms |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
| D012002 | Rectal Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068258 | Bevacizumab |
| D004358 | Drug Therapy |
| ID | Term |
|---|---|
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
| D013812 | Therapeutics |
Not provided
Not provided